EFFICACY AND SAFETY OF SARILUMAB VERSUS ADALIMUMAB IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MONOTHERAPY STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INTOLERANCE OR INADEQUATE RESPONSE TO METHOTREXATE

被引：0
|
作者：
Burmester, G. [1 ,2 ,3 ]
Lin, Y. [4 ]
Mangan, E. [5 ]
Van Hoogstraten, H. [4 ]
Vargas, J. [6 ]
Lee, E. [7 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Free Univ, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Sanofi Genzyme, Bridgewater, MA USA
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Quantum Res, Puerto Varas, Chile
[7] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
INTERNAL MEDICINE JOURNAL | 2017年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P53
引用
收藏
页码：26 / 26
页数：1
相关论文
共 50 条
  • [41] Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial
    Cohen, Stanley
    Tuckwell, Katie
    Katsumoto, Tamiko R.
    Zhao, Rui
    Galanter, Joshua
    Lee, Chin
    Rae, Julie
    Toth, Balazs
    Ramamoorthi, Nandhini
    Hackney, Jason A.
    Berman, Alberto
    Damjanov, Nemanja
    Fedkov, Dmytro
    Jeka, Slawomir
    Chinn, Leslie W.
    Townsend, Michael J.
    Morimoto, Alyssa M.
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (09) : 1435 - 1446
  • [42] Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
    Yoshiya Tanaka
    Kazuteru Wada
    Yoshinori Takahashi
    Owen Hagino
    Hubert van Hoogstraten
    Neil M. H. Graham
    Hideto Kameda
    Arthritis Research & Therapy, 21
  • [43] Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: Results of a randomized double-blind study
    Geusen, P
    Alten, R
    Rovensky, J
    Sloan, V
    Krammer, G
    Kralidis, G
    Richardson, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S242 - S242
  • [44] Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    Gabay, Cem
    Emery, Paul
    van Vollenhoven, Ronald
    Dikranian, Ara
    Alten, Rieke
    Pavelka, Karel
    Klearman, Micki
    Musselman, David
    Agarwal, Sunil
    Green, Jennifer
    Kavanaugh, Arthur
    LANCET, 2013, 381 (9877): : 1541 - 1550
  • [45] Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
    van Riel, P. L. C. M.
    Taggart, A. J.
    Sany, J.
    Gaubitz, M.
    Nab, H. W.
    Pedersen, R.
    Freundlich, B.
    MacPeek, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (11) : 1478 - 1483
  • [46] EFFICACY AND SAFETY OF ADALIMUMAB WITH LOW AND HIGH DOSE-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: THE RANDOMISED CONTROLLED MIRACLE STUDY
    Tamai, H.
    Ikeda, K.
    Miyamoto, T.
    Taguchi, H.
    Kuo, C. F.
    Shin, K.
    Hirata, S.
    Okano, Y.
    Sato, S.
    Yasuoka, H.
    Choi, I. A.
    Park, S. H.
    Weng, M. Y.
    Kuwana, M.
    Lee, Y. J.
    Ishii, T.
    Kim, J.
    Kameda, H.
    Kojima, T.
    Baek, H. J.
    Hsu, P. N.
    Huang, C. M.
    Cheng, T. T.
    Sung, W. Y.
    Taninaga, T.
    Mori, M.
    Miyagishi, H.
    Sato, Y.
    Takeuchi, T.
    Kaneko, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 42 - 43
  • [47] EFFICACY AND SAFETY OF LEVILIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS: PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL
    Mazurov, V.
    Korolev, M.
    Kundzer, A.
    Soroka, N.
    Kastanayan, A.
    Povarova, T.
    Plaksina, T.
    Antipova, O.
    Kretchikova, D.
    Smakotina, S.
    Tciupa, O.
    Raskina, T.
    Kropotina, T.
    Nesmeyanova, O.
    Popova, T.
    Dokukina, E.
    Plotnikova, A.
    Lutskii, A.
    Zinkina-Orihan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 550 - 551
  • [48] Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
    Fiore, Stefano
    Genovese, Mark
    Fan, Chunpeng
    Decktor, Dennis
    Fleischmann, Roy
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1217 - 1217
  • [49] Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
    McInnes, Iain
    Anderson, Jaclyn K.
    Magrey, Marina
    Merola, Joseph
    Liu, Yi
    Kishimoto, Mitsumasa
    Jeka, Slawomir
    Tena, Cesar Pacheco
    Wang, Xin
    Chen, Liang
    Zueger, Patrick
    Pangan, Aileen
    Behrens, Frank
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [50] EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
    Ostor, A.
    Van den Bosch, F.
    Papp, K.
    Asnal, C.
    Blanco, R.
    Aelion, J.
    Alperovich, G.
    Zhang, Y.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 138 - 139
12345